Skip to main content

Table 1 Demographic and Clinical Characteristics at Baseline

From: Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

 

Placebo N = 116

IR-MPH (tid) N = 102

OROS-MPH N = 67

 
 

mean ± sd/N (%)

mean ± sd/N (%)

mean ± sd/N (%)

Omnibus Statistic

Age (years)

38.5 ± 9.1

35.7 ± 9.8

32.7 ± 18.5 *

F(2,282) = 5.0, p = 0.007

Sex (male)

58 (50)

60 (59)

38 (57)

χ2 (2) = 1.8, p = 0.4

Weight (kg)

82.9 ± 18.9

79.9 ± 15.8

84.1 ± 20.1

F(2,282) = 1.3, p = 0.3

ADHD

    

   Onset (years)

5.0 ± 2.9

6.3 ± 6.7

5.2 ± 2.2

F(2,253) = 2.0, p = 0.1

   Symptoms (lifetime)

14.3 ± 2.8

13.5 ± 3.4

14.4 ± 2.7

F(2,248) = 4.3, p = 0.1

   Symptoms (Current)

12.1 ± 3.7

11.5 ± 3.9

12.2 ± 2.9

F(2,248) = 2.0, p = 0.4

CGI Severity

    

   Mild

1 (1)

1 (1)

1 (1)

χ2 (6) = 9.6, p = 0.1

   Moderate

52 (45)

31 (30)

27 (40)

 

   Marked

53 (46)

60 (59)

38 (57)

 

   Severe

10 (9)

10 (10)

1 (1)

 

GAF

    

   Past (worst)

52.2 ± 5.6

52.3 ± 5.9

51.4 ± 4.7

F(2,259) = 0.6, p = 0.5

   Current

59.0 ± 4.9

59.9 ± 5.0

57.8 ± 4.2$

F(2,259) = 4.1, p = 0.02

HAM-A

4.6 ± 3.9

5.8 ± 4.8

4.4 ± 3.8

F(2,281) = 3.2, p = 0.04

HAM-D

4.4 ± 4.5

5.1 ± 5.3

4.8 ± 4.7

F(2.282) = 0.6, p = 0.6

  1. *, p < 0.05 versus Placebo, $, p < 0.05 versus IR-MPH (tid).